The February Peptide Reclassification Almost No One Covered

In February 2026, the U.S. Department of Health and Human Services made a significant change to peptide access that received very little mainstream coverage. It is worth understanding, especially if you follow this space closely. The FDA maintains a list of peptides that compounding pharmacies are permitted to prepare under certain conditions, split into Category 1, which is more available, and Category 2, which is more restricted. In late February, HHS Secretary Robert F. Kennedy Jr. announced that 14 of the 19 peptides sitting in Category 2 would move, not toward greater access, but further into restriction. This runs counter to the deregulation narrative that gets repeated frequently in peptide communities. The actual regulatory direction through 2026 has mostly been tightening rather than loosening. For anyone sourcing research-labeled product online, this does not change what is currently legal to buy or sell. What it does signal is where prescriber-level access is heading, and combined with this year's FDA compounding committee review, the pattern looks consistent: more oversight, not a pathway to easier access. This is exactly the kind of development that is easy to miss if you are only following peptide accounts rather than the underlying regulatory news, which is part of why it is worth documenting here.